Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Asthma Exacerbation Study

ClinicalTrials.gov ID: NCT01086384

Public ClinicalTrials.gov record NCT01086384. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects With Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will establish the safety as well as demonstrate benefit of the addition of a LABA to an ICS by utilizing an endpoint (time to first severe asthma exacerbation) that informs on both safety and efficacy.

Study identification

NCT ID
NCT01086384
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
2,020 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 21, 2010
Primary completion
Aug 31, 2011
Completion
Sep 14, 2011
Last update posted
Jan 23, 2018

2010 – 2011

United States locations

U.S. sites
64
U.S. states
23
U.S. cities
61
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35209
GSK Investigational Site Mobile Alabama 36608
GSK Investigational Site Oxford Alabama 36203
GSK Investigational Site Phoenix Arizona 85016
GSK Investigational Site Scottsdale Arizona 85251
GSK Investigational Site Tucson Arizona 85724-5073
GSK Investigational Site Bell Gardens California 90201
GSK Investigational Site Fresno California 93721
GSK Investigational Site Huntington Beach California 92647
GSK Investigational Site Long Beach California 90808
GSK Investigational Site Los Angeles California 90048
GSK Investigational Site Mission Viejo California 92691
GSK Investigational Site Napa California 94558
GSK Investigational Site Rancho Mirage California 92270
GSK Investigational Site Riverside California 92506
GSK Investigational Site Rolling Hills Estates California 90274
GSK Investigational Site Roseville California 95661
GSK Investigational Site San Diego California 92120
GSK Investigational Site Stockton California 95207
GSK Investigational Site Torrance California 90505
GSK Investigational Site Denver Colorado 80230
GSK Investigational Site Englewood Colorado 80112
GSK Investigational Site Cocoa Florida 32927
GSK Investigational Site Miami Florida 33173
GSK Investigational Site Valrico Florida 33596
GSK Investigational Site Winter Park Florida 32789
GSK Investigational Site Albany Georgia 31707
GSK Investigational Site Columbus Georgia 31904
GSK Investigational Site Lawrenceville Georgia 30046
GSK Investigational Site Coeur d'Alene Idaho 83814
GSK Investigational Site River Forest Illinois 60305
GSK Investigational Site Indianapolis Indiana 46256
GSK Investigational Site Hazard Kentucky 41701
GSK Investigational Site Owensboro Kentucky 42301
GSK Investigational Site Metairie Louisiana 70006
GSK Investigational Site Sunset Louisiana 70584
GSK Investigational Site Baltimore Maryland 21236
GSK Investigational Site Rockville Centre New York 11570
GSK Investigational Site The Bronx New York 10461
GSK Investigational Site Canton Ohio 44718
GSK Investigational Site Cincinnati Ohio 45231
GSK Investigational Site Sylvania Ohio 43560
GSK Investigational Site Oklahoma City Oklahoma 73103
GSK Investigational Site Oklahoma City Oklahoma 73120
GSK Investigational Site Eugene Oregon 97401
GSK Investigational Site Medford Oregon 97504
GSK Investigational Site Collegeville Pennsylvania 19426
GSK Investigational Site Philadelphia Pennsylvania 19107
GSK Investigational Site Philadelphia Pennsylvania 19115
GSK Investigational Site Pittsburgh Pennsylvania 15241
GSK Investigational Site Charleston South Carolina 29407
GSK Investigational Site Gaffney South Carolina 29340
GSK Investigational Site Spartanburg South Carolina 29303
GSK Investigational Site Union South Carolina 29379
GSK Investigational Site Knoxville Tennessee 37909
GSK Investigational Site Austin Texas 78750
GSK Investigational Site Houston Texas 77054
GSK Investigational Site Houston Texas 77074
GSK Investigational Site Killeen Texas 76542
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Waco Texas 76712
GSK Investigational Site South Burlington Vermont 05403
GSK Investigational Site Bellingham Washington 98225
GSK Investigational Site La Crosse Wisconsin 54601

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 119 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01086384, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 23, 2018 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01086384 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →